[go: up one dir, main page]

WO2002016408A3 - Analogues de gpe - Google Patents

Analogues de gpe Download PDF

Info

Publication number
WO2002016408A3
WO2002016408A3 PCT/US2001/041883 US0141883W WO0216408A3 WO 2002016408 A3 WO2002016408 A3 WO 2002016408A3 US 0141883 W US0141883 W US 0141883W WO 0216408 A3 WO0216408 A3 WO 0216408A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpe
gly
pro
glu
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/041883
Other languages
English (en)
Other versions
WO2002016408A2 (fr
Inventor
Peter Gluckman
Tajrena Alexi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuronz Ltd
Original Assignee
Neuronz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronz Ltd filed Critical Neuronz Ltd
Priority to EP01968959A priority Critical patent/EP1351976A2/fr
Priority to US10/362,266 priority patent/US7112570B2/en
Priority to AU2001289160A priority patent/AU2001289160A1/en
Publication of WO2002016408A2 publication Critical patent/WO2002016408A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002016408A3 publication Critical patent/WO2002016408A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des analogues de GPE, en particulier, des analogues de GPE capables d'induire un effet physiologique équivalent à GPE chez un patient. Ces analogues de GPE consistent en des peptides dans lesquels le Gly de Gly-Pro-Glu est remplacé par Ala ou Ser ou Thr ou Pro, le Pro de Gly-Pro-Glu est remplacé par Ala ou Ser ou Thr ou Gly et le Glu de Gly-Pro-Glu étant remplacé par Asn ou Asp ou Gln. Ces analogues de GPE peuvent être utilisés dans tout procédé thérapeutique ou prophylactique impliquant GPE. Ces utilisations comprennent le traitement de lésions cérébrales aiguës et de maladies neurodégénératives, y compris, sans limitation, des lésions ou des maladies du système nerveux central. On administrera normalement ces analogues de GPE dans une composition ou une préparation pharmaceutique.
PCT/US2001/041883 2000-08-24 2001-08-24 Analogues de gpe Ceased WO2002016408A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01968959A EP1351976A2 (fr) 2000-08-24 2001-08-24 Analogues de gpe
US10/362,266 US7112570B2 (en) 2000-08-24 2001-08-24 GPE analogs
AU2001289160A AU2001289160A1 (en) 2000-08-24 2001-08-24 Gpe analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ506534 2000-08-24
NZ50653400 2000-08-24

Publications (2)

Publication Number Publication Date
WO2002016408A2 WO2002016408A2 (fr) 2002-02-28
WO2002016408A3 true WO2002016408A3 (fr) 2003-04-24

Family

ID=19928066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041883 Ceased WO2002016408A2 (fr) 2000-08-24 2001-08-24 Analogues de gpe

Country Status (3)

Country Link
EP (1) EP1351976A2 (fr)
AU (1) AU2001289160A1 (fr)
WO (1) WO2002016408A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041314B2 (en) 2001-05-24 2006-05-09 Neuren Pharmaceuticals Ltd. GPE analogs and peptidominetics
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
FR2827170B1 (fr) * 2001-07-13 2004-07-16 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
WO2007079977A2 (fr) * 2006-01-16 2007-07-19 Dsm Ip Assets B.V. Nouvelles préparations nutraceutiques et applications
WO2008153929A1 (fr) 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Traitement du syndrome de rett et d'autres troubles
BR112013018898B1 (pt) 2011-01-27 2021-10-05 Neuren Pharmaceuticals Limited Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
GB201613999D0 (en) * 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders
US20230312643A1 (en) * 2020-09-08 2023-10-05 Sunmarine Biotech Peptide derivative with collagenase inhibitory activity, and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906614A (en) * 1985-01-23 1990-03-06 Gruenenthal Gmbh Method of treating posttraumatic nervous injuries with dipeptide derivatives
EP0366638A2 (fr) * 1988-10-27 1990-05-02 KabiGen AB Peptides neuromodulatoires
WO1993021216A1 (fr) * 1992-04-14 1993-10-28 Russian-American Institute For New Drug Development N-acylprolyldipeptides biologiquement actifs, presentant des effets antiamnesiques, antihypoxie et anorexigenes
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
WO1995017204A1 (fr) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition et procedes permettant d'ameliorer l'issue d'etats pathologiques du systeme nerveux
WO2000013650A2 (fr) * 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906614A (en) * 1985-01-23 1990-03-06 Gruenenthal Gmbh Method of treating posttraumatic nervous injuries with dipeptide derivatives
EP0366638A2 (fr) * 1988-10-27 1990-05-02 KabiGen AB Peptides neuromodulatoires
WO1993021216A1 (fr) * 1992-04-14 1993-10-28 Russian-American Institute For New Drug Development N-acylprolyldipeptides biologiquement actifs, presentant des effets antiamnesiques, antihypoxie et anorexigenes
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
WO1995017204A1 (fr) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition et procedes permettant d'ameliorer l'issue d'etats pathologiques du systeme nerveux
WO2000013650A2 (fr) * 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection

Also Published As

Publication number Publication date
WO2002016408A2 (fr) 2002-02-28
AU2001289160A1 (en) 2002-03-04
EP1351976A2 (fr) 2003-10-15

Similar Documents

Publication Publication Date Title
BG66083B1 (bg) Фармацевтични състави, съдържащи антитела и антитела за профилактика и лечение на амилоидогенно заболяване
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
TW264480B (fr)
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
WO2004041067A3 (fr) Prevention et traitement d'une maladie synucleopathique
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
PL349335A1 (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
WO2002016408A3 (fr) Analogues de gpe
WO2001053457A3 (fr) Vaccins contre certains troubles neurodegeneratifs
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
WO2003034996A3 (fr) Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
BR0210473A (pt) Composição compreendendo um inibidor da pde-4 e antagonista do receptor-h1 e seus usos na produção de um medicamento para o tratamento de doenças respiratórias
WO2000072823A8 (fr) Preparations pour l'application d'agents anti-inflammatoires
WO2002046221A3 (fr) Proteines
WO2002051379A3 (fr) Aerosol nasal thixotropique
WO2005046605A3 (fr) Compositions et procedes de traitement de maladies nerveuses
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
JP4445263B2 (ja) 経皮薬物送達システム
GB2311724A (en) New applications of lysozyme dimer
ES2299877T3 (es) Uso de extractos de especies de pelargonio.
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales
WO2005123651A8 (fr) L-2-(a-hydroxypentyle)benzoates, leur elaboration et leur utilisation
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001968959

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10362266

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001968959

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP